SCHEMBL13780252

SCHEMBL13780252

Cc1cc2nc(Cl)nc(NCc3ccc(Cl)cc3Cl)c2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CD38 P28907 1/20 0.38
P2RX7 Q99572 1/20 0.38
CCR4 P51679 3/20 0.37
KCNH2 Q12809 1/20 0.37
PDE2A O00408 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
GPR39 O43194 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTT P42858 2/20 0.36
SLC2A1 P11166 1/20 0.36
EIF2AK1 Q9BQI3 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13780280 0.81 PRKCQ (0.42) HPGDNPSR1MEN1KMT2AMAPT
SCHEMBL4208839 0.80 PDE4A (0.41) HPGDNPSR1
SCHEMBL13780250 0.77 HDAC1 (0.41) HPGDNPSR1MEN1KMT2ACD38
SCHEMBL13780251 0.74 APP (0.63) HPGDNPSR1MEN1KMT2ACCR4
SCHEMBL4206499 0.73 PDE2A (0.42) HPGDNPSR1MEN1KMT2AP2RX7
SCHEMBL21214764 0.73 HPGD (0.45) HPGDNPSR1MEN1KMT2ACD38
SCHEMBL13777948 0.72 ESR1 (0.61) HPGDNPSR1MEN1KMT2ACD38
SCHEMBL13777965 0.72 PDE2A (0.52) HPGDNPSR1P2RX7CCR4PDE2A
SCHEMBL13780274 0.68 HPGD (0.51) HPGDNPSR1CD38CCR4HDAC1
SCHEMBL13780267 0.68 EGFR (0.44) HPGDNPSR1MEN1KMT2ACCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
US-20090182140-A1 Alicyclic Heterocyclic Compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-07-16 US disclosed
EP-1970373-A1 ALICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182140-A1 Alicyclic Heterocyclic Compound CCR4, CCR1, HRH4 HPGD 1929/4885NPSR1 2574/4885MEN1 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.